One study that adopted whole-genome/exome sequencing (WGS/WES) of 619 patients with DLBCL revealed that somatic mutations in KMT2D (19.5%) were most frequently observed, followed by mutations in ARID1A (8.7%), CREBBP (8.4%), KMT2C (8.2%), TET2 (7.8%), EP300 (6.8%), and EZH2 (2.9%) (17). Here, CREBBP is linked to diffuse large B-cell lymphoma.